Endothelial progenitor cells show potential as biomarkers for cardiovascular diseases, though clinical application requires standardized phenotypic definitions and updated isolation methods.
Endothelial progenitor cells (EPC) may influence the integrity and stability of the vascular endothelium. The association of an altered total EPC number and function with cardiovascular diseases (CVD) and risk factors (CVF) was discussed; however, their role and applicability as biomarkers for clinical purposes have not yet been defined. Endothelial dysfunction is one of the key mechanisms in CVD. The assessment of endothelial dysfunction in vivo remains a major challenge, especially for a clinical evaluation of the need for therapeutic interventions or for primary prevention of CVD. One of the main challenges is the heterogeneity of this particular cell population. Endothelial cells (EC) can become senescent, and the majority of circulating endothelial cells (CEC) show evidence of apoptosis or necrosis. There are a few viable CECs that have properties similar to those of an endothelial progenitor cell. To use EPC levels as a biomarker for vascular function and cumulative cardiovascular risk, a correct definition of their phenotype, as well as an update on the clinical application and practicability of current isolation methods, are an urgent priority.
Heinisch et al. (Wed,) conducted a review in Cardiovascular diseases. Endothelial progenitor cells (EPC) as biomarkers was evaluated. Endothelial progenitor cells show potential as biomarkers for cardiovascular diseases, though clinical application requires standardized phenotypic definitions and updated isolation methods.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: